id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3572-0007,FDA,FDA-2024-E-3572,Determination of Regulatory Review Period for Purposes of Patent Extension; TEVIMBRA,Notice,Determinations,2026-02-26T05:00:00Z,2026,2,2026-02-26T05:00:00Z,2026-04-28T03:59:59Z,2026-02-26T20:52:55Z,2026-03851,1,0,09000064b91deb48